TECVAYLI™▼ (teclistamab) Patient Card

Carry this card with you at all times. SHOW THIS CARD to any healthcare professional involved in your care and if you go to the hospital. TECVAYLI can cause side effects such as Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).[1]

Patient's Name: _____

Important Safety Information for Patients

Get medical help straight away if you experience any of the following:[1]

Cytokine Release Syndrome (CRS)

- Fever (38°C or higher), Chills, Fast heartbeat, Difficulty breathing, Nausea, Headache, Feeling dizzy.

Neurologic toxicity, including ICANS

- Feeling confused, Feeling less alert, Having difficulty writing, Having difficulty speaking, Sleepiness, Loss of ability to carry out skilled movement and gestures (despite having the physical ability and desire to perform them)

Important to Remember:

Stay close to the location where you received your TECVAYLI therapy for at least 2 days for daily monitoring after administration of your first three doses (usually two step-up doses and first maintenance dose).[1] If you have any of the symptoms listed on this card call your doctor or seek emergency medical attention right away! These are not all the possible side effects of TECVAYLI. Tell your doctor if you have any side effect that bothers you or does not go away.

Treating Physician

Treating Physician's Name: _____ Treating Physician's Phone Number: _____

Hospital's Name And Address: _____ Hospital's Phone Number: _____

Information for Healthcare Team to Fill In

Please give this card to your healthcare team to fill in the information and return to you.

Dates of TECVAYLI injections (step-up dosing schedule):

STEP-UP DOSE 1 _____ **STEP-UP DOSE 2** _____

FIRST MAINTENANCE DOSE* _____

*This is the first full treatment dose (1.5 mg/kg)[1]

Important Safety Information for Healthcare Professionals

CRS and neurologic toxicity, including ICANS, may occur in patients receiving TECVAYLI, and can be fatal or life-threatening. The majority of these events observed following TECVAYLI administration were Grade 1 and 2.[1]
Assess the patient for signs and symptoms of CRS and ICANS. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's treating physician immediately for further information.

See Summary of Product Characteristics for full details.[1]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
1. TECVAYLI (teclistamab), EU SmPC, July 2025.
TECVAYLI™ is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.

CONTACTS

For Adverse Events or safety related issues, please approach group mailbox: **PVNEMA@its.jnj.com**
For Product Quality Complaints and Temperature Excursions, please approach group mailbox: **QANEMA@its.jnj.com**
For Medical Information please approach group mailbox: **Medical-info@its.jnj.com**

ADDRESS

Johnson & Johnson Middle East FZ-LLC Lebanon Branch
Sin El Fil, General Chehab Avenue, Paul Habbouche Building,
Near Clinique Du Levant
P.O Box: 55-325 Beirut - Lebanon
Phone: +9611518700 / Fax: +961 1518797

CP-575107

Johnson&Johnson